One of Nigeria's leading pharmaceutical companies, Zadip Healthcare LTD, has introduced a new Anti-malaria medication called Medither-DS. Laris is an anti-malaria drug with 480 mg Lumefentrin and 80mg Artemether, a powerful Arteminism Combination Therapy, (ACT).

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes.

Plasmodium falciparum malaria is the most common type of malaria found in Sub-Saharan Africa and responsible for more than 880,0000 malaria-related fatalities that occur a year.

According to research by the World Health Organisation, artemisinin-based combination therapy (ACT) regimens have been shown to effectively treat Plasmodium falciparum malaria cases in endemic areas.

Due to its efficacy, ACT malaria drugs are considered one of the best and most sought after in the market, making it expensive for some consumers.

Malaria sufferers will be happy to learn that Medither-DS offers quality treatment at an affordable price. The introduction of this new and effective anti-malaria medication is a great feat in the fight against Malaria in Nigeria.

For Zadip Healthcare Ltd, launching Medither-DS is another step in expanding the company’s pharmaceutical portfolio.

With its fully integrated logistics, warehousing and sales operations, as well as its strong distribution networks across Nigeria and within the West African Sub-region, industry watchers predict that with the launch of Medither-DS, a large chunk of ACT malaria drug market will be captured by Zadip Healthcare Ltd.

Sounds exciting. Whats the whatsapp number?